PLG and cancer: An increasing number of studies have identified eATP synthase as a potential molecular target for cancer therapy16–18, with supporting findings indicating that angiostatin, a C-terminal fragment peptide derived from plasminogen by serine proteinase cleavage19,20, and antibodies against ATP synthase subunits α and β markedly suppress the enzymatic activity of eATP synthase on the cell surface.